Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million
Rhea-AI Summary
Galecto (NASDAQ: GLTO) closed an underwritten public offering of 16,644,737 common shares at $19.00 per share, including full exercise of the underwriters’ option for 2,171,052 additional shares. Gross proceeds were approximately $316.3 million before underwriting discounts, commissions and offering expenses.
Jefferies, Leerink Partners, Evercore ISI and Guggenheim Securities acted as joint book-running managers. The offering was made from an effective shelf registration dated February 10, 2026, and final prospectus documents were filed with the SEC.
Positive
- Gross proceeds of $316.3 million
- Offering fully subscribed including 2,171,052 option shares
- Price per share set at $19.00
Negative
- Share issuance of 16,644,737 may dilute existing shareholders
- Net proceeds reduced by underwriting discounts, commissions and expenses
News Market Reaction – GLTO
In the Feb 13 session, GLTO declined 3.03%, reflecting a moderate negative market reaction. Argus tracked a peak move of +61.1% during that session. Our momentum scanner triggered 33 alerts that day, indicating elevated trading interest and price volatility. Trading volume was exceptionally heavy at 5.7x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 10 | Offering priced | Negative | -10.3% | Priced $275M common stock offering at $19.00 with underwriter option. |
| Feb 10 | Offering proposed | Negative | -10.3% | Proposed common and Series C preferred stock offering for pipeline funding. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent equity offerings for GLTO have prompted consistently negative reactions, with an average -10.33% move on past offering announcements.
In early February 2026, Galecto announced and priced an underwritten public offering of common stock and Series C non-voting convertible preferred stock, including a $275 million common-stock tranche at $19.00 per share. These equity financings, conducted off an automatic shelf registration, saw shares fall about 10.33% the next day. Today’s release confirms closing and full exercise of the underwriters’ option, extending that February financing sequence and building on the company’s broader capital-raising strategy highlighted in recent filings.
Key Terms
underwritten public offering financial
shelf registration statement regulatory
prospectus supplement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced the closing of its previously announced underwritten public offering of 16,644,737 shares of its common stock, including the full exercise of the underwriters’ option to purchase up to 2,171,052 additional shares, at a public offering price of
Jefferies, Leerink Partners, Evercore ISI and Guggenheim Securities acted as joint book-running managers for the offering.
An automatically effective shelf registration statement relating to these securities was filed with the Securities and Exchange Commission (SEC) on February 10, 2026. This offering was made only by means of a written prospectus, including a prospectus supplement, forming a part of an effective registration statement. A copy of the final prospectus supplement and the accompanying prospectus relating to the offering have been filed with the SEC, are available on the SEC’s website at www.sec.gov and may be obtained from: Jefferies LLC (Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022; telephone: 877-821-7388; or email: Prospectus_Department@Jefferies.com); Leerink Partners LLC (Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109; telephone: 800-808-7425 ext. 6105; or email: syndicate@leerink.com); Evercore Group L.L.C. (Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055; telephone: 888-474-0200; or email: ecm.prospectus@evercore.com); or Guggenheim Securities, LLC (Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, New York 10017; telephone: 212-518-9544; or email: GSEquityProspectusDelivery@guggenheimpartners.com).
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Galecto, Inc.
Galecto, Inc. is a clinical-stage biotechnology company advancing a pipeline of antibody therapeutics to transform treatment of a broad spectrum of hematological cancers. Galecto’s pipeline includes a highly differentiated mutant calreticulin (mut-CALR)-driven myeloproliferative neoplasm portfolio targeting essential thrombocythemia and myelofibrosis. Galecto’s pipeline also includes GB3226, a first-in-class preclinical dual inhibitor of ENL-YEATS and FLT3 for the treatment of multiple genetic subsets of acute myeloid leukemia.
Media Contact:
Lia Dangelico
Deerfield Group
lia.dangelico@deerfieldgroup.com
Investor Contact:
Brian Ritchie
LifeSci Advisors
britchie@lifesciadvisors.com
